康方生物-B(09926.HK)擬根據一般授權配售3000萬股新股
格隆匯 1 月 7日丨康方生物-B(09926.HK)發佈公吿,2021年1月7日(交易時間前),公司與配售代理摩根士丹利訂立配售協議,據此,公司已有條件同意透過配售代理,以每股配售股份39.60港元的價格,向不少於六名承配人配售合共3000萬股配售股份。
配售股份相當於該公吿日期公司現有已發行股本約3.81%及緊隨配售後公司經擴大已發行股本約3.67%(假設最高配售股份數目已獲配售且自該公吿日期起直至配售完成之日止公司的已發行股本並無變動)。配售股份將根據一般授權配發及發行,無需股東批准。假設3000萬股配售股份獲悉數認購,配售完成後,所得款項總額將為11.88億港元,配售所得款項淨額估計為11.7134億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.